Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice

Biomedical Chromatography

Volumn 29, Issue 5, 2015, Pages 654-663

  Nag, Subhasree ^a   Qin, Jiang Jiang ^a   Voruganti, Sukesh ^a   Wang, Ming Hai ^a   Sharma, Horrick ^b   Patil, Shivaputra ^b   Buolamwini, John K ^b   Wang, Wei ^a   Zhang, Ruiwen ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

HPLC; Pharmacokinetics; Pyrido b indole; SP 141

Indexed keywords

MAMMALS; POLYCYCLIC AROMATIC HYDROCARBONS; TUMORS;

ANTI-CANCER AGENTS; CANCER THERAPY; HPLC; HPLC METHOD; IN-VITRO; PHARMACOKINETIC STUDIES; PYRIDO[B]INDOLE; SMALL MOLECULES; SP-141; VITRO AND IN VIVO;

PHARMACOKINETICS;

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MICROSOME ENZYME; PYRIDO[B]INDOLE ANTICANCER AGENT; UNCLASSIFIED DRUG; 6-METHOXY-1-(NAPHTHALEN-1-YL)-9H-PYRIDO(3,4-B)INDOLE; PYRIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HOMOGENATE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HEART HOMOGENATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOGENATE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY HOMOGENATE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER HOMOGENATE; LUNG HOMOGENATE; MOUSE; NONHUMAN; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SPLEEN HOMOGENATE; TISSUE DISTRIBUTION; TISSUE HOMOGENATE; VALIDATION STUDY; ANIMAL; BLOOD; EVALUATION STUDY; HALF LIFE TIME; HUMAN; NEOPLASMS; NUDE MOUSE; PROCEDURES;

MUS; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HUMANS; INDOLES; MICE; MICE, NUDE; NEOPLASMS; PYRIDINES; TISSUE DISTRIBUTION;

EID: 84927795159     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3327     Document Type: Article

References (32)

1. Agrawal S, Zhang X, Cai Q, Kandimalla ER, Manning A, Jiang Z, Marcel T and Zhang R. Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats. Journal of Drug Targeting 1998; 5: 303-312.
2. Bansal S and DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS Journal 2007; 9: E109-E114.
3. Cao H, Le D and Yang LX. Current status in chemotherapy for advanced pancreatic adenocarcinoma. Anticancer Research 2013; 33: 1785-1791.
4. CDER/US FDA. Guidance for Industry: Bioanalytical Methods Validation, 2007. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed 4 April 2014).
5. Chen L, Agrawal S, Zhou W, Zhang R and Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 195-200.
6. Ezell SJ, Li H, Xu H, Gurpinar E, Zhang X, Rayburn ER, Sommers CI, Yang X, Velu SE, Wang W and Zhang R. Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent. Marine Drugs 2010; 8: 2129-2141.
7. Gad SC. Preclinical Development Handbook: ADME and Biopharmaceutical Properties. John Wiley & Sons: Hoboken, NJ, 2008.
8. Hao M, Wang W, Zhao Y, Zhang R and Wang H. Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors. European Journal of Drug Metabolism and Pharmacokinetics 2011; 35: 109-113.
9. Ji AJ, Jiang Z, Livson Y, Davis JA, Chu JX and Weng N. Challenges in urine bioanalytical assays: overcoming nonspecific binding. Bioanalysis 2010; 2: 1573-1586.
10. Lee MS. LC/MS Applications in Drug Development. John Wiley & Sons: Hoboken, NJ, 2003.
11. Nag S, Qin JJ, Srivenugopal K, Wang MH and Zhang R. MDM2-p53 pathway revisited. Journal of Biomedical Research 2013; 27: 254-271.
12. Paulson AS, Tran Cao HS, Tempero MA and Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013; 144: 1316-1326.
13. Qin JJ, Nag SN, Voruganti S, Wang W and Zhang R. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action. Current Medicinal Chemistry 2012; 19: 5705-5725.
14. Rayburn E, Zhang R, He J and Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Current Cancer Drug Targets 2005; 5: 27-42.
15. Rayburn E, Wang W, Li M, Zhang X, Xu H, Li H, Qin JJ, Jia L, Covey J, Lee M and Zhang R. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anti-cancer agent. Cancer Chemotherapy and Pharmacology 2012; 69: 1423-1431.
16. Scheife RT. Protein binding: what does it mean? DICP 1989; 23: S27-S31.
17. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 2013; 63: 11-30.
18. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Current Drug Metabolism 2006; 7: 165-182.
19. Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K and Mackie CE. Predicting oral clearance in humans: how close can we get with allometry? Clinical Pharmacokinetics 2008; 47: 35-45.
20. Wang W, Wang H, Rayburn E, Zhao Y, Hill D and Zhang R. 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. British Journal of Cancer 2008; 98: 792-802.
21. Wang W, Rayburn ER, Zhao Y, Wang H and Zhang R. Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Letter 2009a; 278: 241-248.
22. Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S and Zhang R. In vitro and in vivo anticancer activity of makaluvamine analogues. Clinical Cancer Research 2009b; 15: 3511-3518.
23. Wang W, Ao L, Rayburn ER, Xu H, Zhang XR, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG and Zhang R. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS ONE 2012; 7: e44883.
24. Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice. Gastroenterology 2014.
25. Wang W, Qin JJ, Voruganti S, Srivenugopal K, Nag S, Patil S, Sharma H, Wang MH, Wang H, Buolamwini JK, Zhang R. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nature Communications 2014.
26. Wolfender JL. HPLC in natural product analysis: the detection issue. Planta Medica 2009; 75: 719-734.
27. Zhang R and Wang H. MDM2 oncogene as a novel target for human cancer therapy. Current Pharmaceutical Design 2000; 6: 393-416.
28. Zhang Z, Li M, Wang H, Agrawal S and Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 11636-11641.
29. Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner J, Agrawal S and Zhang R. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clinical Cancer Research 2004; 10: 1263-1273.
30. Zhang R, Wang H and Agrawal S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Current Cancer Drug Targets 2005; 5: 43-50.
31. Zhang X, Xu H, Xu Z, Sukesh V, Srinivasan M, Dwayaja NH, Sadanandan VE, Wang M-H, Wang W and Zhang R. Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog. Marine Drugs 2012; 10: 1138-1155.
32. Zhou S, Kestell P and Paxton JW. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metabolism Reviews 2002; 34: 751-790.